´ëÇѺñ´¢ÀÇÇÐȸ 2019 Annual Meeting of KUA : 2019-10-31±³À°ÀÏÀÚ : 2019-10-31
±³À°Àå¼Ò : ¼¿ï COEX 202È£ ¿Ü
±³À°ÁÖÁ¦ :
2019 Annual Meeting of KUA ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
´ã´çÀÚ : ·ùÇö¿µ
¿¬¶ôó : 02-573-8190
À̸ÞÀÏ :
urotraining@urology.or.kr ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 15000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 165,000¿ø
ºñ°í Á¤È¸¿ø/±¹Á¦È¸¿ø(»çÀüµî·Ï:110000,ÇöÀåµî·Ï150000), ±ºÀÇ°ü/Àü°øÀÇȸ¿ø/°£È£»ç(»çÀüµî·Ï:66000, ÇöÀåµî·Ï:88000),Ÿ°úÀü¹®ÀÇ(»çÀüµî·Ï:120000,ÇöÀåµî)¿¬±¸¿ø(»çÀüµî·Ï:66000,ÇöÀåµî·Ï:77000)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-31 ¼¿ï COEX( 102+103È£) 09:30~09:45 Daily highlight °¹Î¿ë(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX( 102+103È£) 09:45~10:00 What is the new concept of flexible ureteroscopy? Á¶¼º¿ë(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(202È£) 10:00~10:05 SP½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ ´ÜÀÏ°ø ·Îº¿ ºÎºÐ½ÅÀýÁ¦¼ú ³ªÁØä(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(203È£) 10:05~10:10 ´ÜÀÏ µµÅ·,¾Ó¿ÍÀ§¸¦ ÀÌ¿ëÇÑ ·Îº¿ ÁÂÃø ½ÅÀå ÀýÁ¦¼ú ¹× ´ëÁ¤¸Æ Ç÷ÀüÁ¦°Å¼ú Çã°æÀç(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(204È£) 10:10~10:15 da Vinci SP¢ç ½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ ¼Ò¾ÆȯÀÚÀÇ ´ÜÀÏÆ÷Æ® ½Å¿ì¼ºÇü¼ú ÀÌ¿ë½Â(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(205È£) 10:15~10:20 ´ÙºóÄ¡ SP ½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ ´ÜÀÏ°ø ·Îº¿º¸Á¶ ±ÙÄ¡ÀûÀü¸³¼±ÀýÁ¦¼ú: ´ÜÀϼúÀÚ °æÇè ±è±¤Çö(ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(206È£) 10:20~10:25 ÈÄÃø ½Å¹®ºÎÁ¾¾ç¿¡¼ ·Îº¿ºÎºÐ½ÅÀýÁ¦¼ú Áß ÀûÀýÇÑ Á¾¾ç³ëÃâÀ» È®º¸Çϱâ À§ÇÑ ¹æ¹ý: Ç÷°ü·çÇÁ¸¦ ÀÌ¿ëÇÑ Ç÷°ü °ßÀμú ±èÁ¾¿ø(¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(207È£) 10:25~10:30 Robot assisted laparoscopic salvage pyeloplasty using flap technique Á¤ÀçÈÆ(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(208È£) 10:30~10:35 ICG Çü±¤ ¿µ»óÀ» ÀÌ¿ëÇÑ ·Îº¿ÀÌ¿ë ±ÙÄ¡Àû ¹æ±¤ÀýÁ¦¼ú ¹× ü³» ȸÀåµµ°ü¼ú Àüº´Á¶(°í·Á´ëÇб³ ¾È¾Ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(209È£) 10:35~11:00 Pure single-site robot-assisted pyeloplasty with the da Vinci SP¢ç system: Initial experience ÇãÁöÀº(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(210È£) 11:00~11:05 ³ÀÓ³²¼º¿¡¼ ½ÃÇàÇÑ Á¤¾×°Ë»çÀÇ º¯µ¿¼º ±èµ¿¼®(CHAÀÇ°úÇдëÇб³ °³²Â÷º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(211È£) 11:05~11:10 Combined Treatment with Extracorporeal Shockwave Therapy and an Herbal Formulation for Synergistic Antioxidation via the Nrf2/HO-1 Signaling Pathway for Diabetic Erectile Dysfunction Á¶½ÅÁ¦(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(212È£) 11:10~11:15 ³²¼º°»³â±â ȯÀÚ¿¡¼ Å×½ºÅ佺Å×·Ð º¸Ãæ¿ä¹ýÀÌ physical fitness¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú physical fitnessÀÇ º¯È¿Í °»³â±â Áõ»ó°úÀÇ »ó°ü°ü°è ºÐ¼® ¹Ú¹Î±¸(ÀÎÁ¦´ëÇб³ ¼¿ï¹éº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(213È£) 11:15~11:20 skin auto fluorescence ·Î ÃøÁ¤ÇÑ ÃÖÁ¾´çȻ깰ÀÇ ´ç´¢º´¼º ¹ß±â ºÎÀü ¹× ºñ ´ç´¢º´¼º ¹ß±â ºÎÀü°úÀÇ »ó°ü °ü°è ¾È¼øÅÂ(°í·Á´ëÇб³ ±¸·Îº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(214È£) 11:20~11:25 ÇÊ·¯¸¦ ÀÌ¿ëÇÑ À½°æ µÑ·¹ È®´ë°¡ »çÁ¤¿¡ ¹ÌÄ¡´Â ¿µÇ⠾ȼøÅÂ(°í·Á´ëÇб³ ±¸·Îº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(215È£) 11:25~11:30 PSA°¡ Ç÷û Å×½ºÅ佺Å×·ÐÀÇ Ç¥ÁöÀÚ·Î »ç¿ëµÉ¼ö Àִ°¡? - ü°èÀû °ËÅä ¹× ¸ÞŸ ºÐ¼® ¹ÚÀçÁØ(¼øõÇâ´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(216È£) 11:30~11:35 °íȯÁ¤ÀÚ Ã¤Ãë½Ã±â°¡ ³ÀӺκÎÀÇ Ã¼¿Ü¼öÁ¤½Ã¼ú¿¡ ¹ÌÄ¡´Â ¿µÇ⠺м® ¼Û½ÂÈÆ(Â÷ÀÇ°úÇÐ´ë °³²Â÷º´¿ø ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 10-31 ¼¿ï COEX(217È£) 11:35~11:40 Optimizing AMS questionnaire through genetic algorithms based machine learning techniques ±èÁø¿í(Áß¾Ó´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(218È£) 11:40~11:45 Áß³â ¹× ³ë³â³²¼º¿¡¼ Æ÷½ºÆ÷µð¿¡½ºÅͶóÁ¦-5¾ïÁ¦Á¦¿Í ¾ËÄÚ¿ÃÀÇ µ¿½Ã »ç¿ëºóµµ¿¡ ´ëÇÑ ¿ªÇבּ¸ ¹× °ü·ÃºÎÀÛ¿ë ºñ±³ºÐ¼® À¯¿µµ¿(CHAÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(219È£) 11:45~11:50 Busulfan À¯µµ »ý½Ä´ÉÀúÇÏ µ¿¹° ¸ðµ¨¿¡¼ N-acetyl-L-cysteineÀÇ °íȯ Á¶Á÷¿¡ ´ëÇÑ È¿°ú ±è°æȯ(ºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(220È£) 11:50~12:00 À½°æÈ®´ë¼ú½Ã Ãʱâ±â°£¿¡ µ¿Á¾ÁøÇÇ¿Í ÀÌÁ¾ÁøÇÇ°£ÀÇ ¾ÈÁ¤¼º¿¡ Â÷ÀÌ°¡ Àִ°¡? È«¼º¿ì(¿¹ÀÛ º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(221È£) 13:00~13:05 ¸ÅÀÏ alfuzosin 10mg °æ±¸ ¿ä¹ý¿¡ ÃæºÐÈ÷ ¹ÝÀÀÇÏÁö ¾Ê´Â ³²¼º ¹è´¢Àå¾Ö/Àü¸³¼±ºñ´ë ȯÀÚ¿¡¼ ¸ÅÀÏ tadalafil 5mg Ãß°¡ º´¿ë¿ä¹ý ½ÃÇàÀÇ È¿°ú¿Í ¾ÈÁ¤¼º ±èÁ¤ÁØ(°¡Å縯´ëÇб³ ÀÎõ¼º¸ðº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(222È£) 13:05~13:10 ÇϺοä·ÎÁõ»óÀÌ ÀÖ´Â Àü¸³¼±ºñ´ëÁõ ȯÀÚ¿¡¼ tamsulosin 0.2mg ´Üµ¶¿ä¹ý°ú tamsulosin 0.2mg, finasteride 5mg º´ÇÕ¿ä¹ýÀÇ À¯È¿¼º ¹× ¾ÈÀü¼ºÀ» Æò°¡Çϱâ À§ÇÑ ´Ù±â°ü, ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², À§¾à´ëÁ¶, ÆòÇàºñ±³ Á¶Á¤¸¸(À»Áöº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(223È£) 13:10~13:15 °èÀý¿¡ µû¸¥ ³²¼º °ú¹Î¼º¹æ±¤ÀÇ À¯º´À² º¯È: ±¹¹Î°Ç°º¸Çè û±¸ÀÚ·á ºÐ¼® ±èÁ¾¿ø(¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(224È£) 13:15~13:20 Èí¿¬ÀÌ ³ëÀÎ ³²¼¿¡¼ ÇϺοä·ÎÁõ»ó ¹× ¹ß±âºÎÀüÀÇ ¾ÇÈ¿¡ ¹ÌÄ¡´Â È¿°ú: ÇѸ² °í·ÉÈ ¿¬±¸ ±èÁ¾±Ù(ÇѸ²´ëÇб³ µ¿Åº¼º½Éº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(225È£) 13:20~13:25 ¹æ±¤ Ãⱸ Æó»ö ¿ÏÈ Áã¸ðµ¨¿¡¼ ¹æ±¤ ¥á©û¾Æµå·¹³¯¸°¼ö¿ëü ¾ÆÇüÀÇ ¹ßÇö ÀÌÁö¿ë(Ãæ³²´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(226È£) 13:25~13:30 Àü¸³¼± ºñ´ëÁõ ȯÀڵ鿡°Ô ¾ËÆĺí·ÏÄ¿¿Í Ä¡¸Å¹ß»ý°úÀÇ °ü°è : ½ÉÆò¿ø ºòµ¥ÀÌÅ͸¦ ÀÌ¿ëÇÑ ºÐ¼® Źü½Ä(°í·Á´ëÇб³ ¾È»êº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(227È£) 13:30~13:35 ´ë»ç¼º ÁõÈıº »óÅÂÀÇ º¯È¿Í Àü¸³¼± ¿ëÀû º¯ÈÀÇ ¿¬°ü¼º¿¡ ´ëÇÑ ´Ù±â°ü, 5³â Á¾´Ü ¿¬±¸ °æÀ±¼ö(¿ï»ê´ëÇб³ ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(228È£) 13:35~13:40 ¿ä·Î»óÇÇ¿¡¼ °ú¹Î¼º ¹æ±¤ ¹ß»ý°ú °ü·ÃµÈ ½ÅÈ£ Àü´Þ ü°è ÀÌÀç±Ù(Ãæ³²´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(229È£) 13:40~13:45 Àü¸³¼±ºñ´ëÁõ ȯÀÚ¿¡¼ Àü¸³¼±ÀÇ Å©±â º¯È¿¡ ÀúÇ×Áö¼öÀÇ °¡Ä¡: ÀüÇâÀû ¿¬±¸ ÀÌ°æ¼·(µ¿±¹´ëÇб³ °æÁÖº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(230È£) 13:45~13:50 Correlation Between the National Institutes of Health Chronic Prostatitis Symptom Index and the International Prostate Symptom Score: A Retrospective Analysis of 870 Korean Men Aged 40–69 Years À̹ÎÈ£(â¿ø°æ»ó´ëº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(231È£) 13:50~14:00 ¹è´¢ Áõ»ó ¹× ¿ä È帧¿¡¼ÀÇ Àü¸³¼± ÃⱸºÎÀÇ ¿ªÇÒ ¹ÚÁö¼ö(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(232È£) 14:00~14:05 °ø¿©½ÅÀûÃâ¼ú ÈÄ °¨¼ÒÇÑ ¿©°úÀ²ÀÌ ¸¸¼º½ÅºÎÀüÀ» ÀǹÌÇÏÁö ¾Ê´Â´Ù: ´¢NGALÀ» Àå±â°£ ÃßÀû°üÂûÇÑ ¿¬±¸ ³ªÁØä(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(233È£) 14:05~14:10 ±âÁõ Àü ¹Ì¼¼ ´Ü¹é´¢°¡ ÀÖ´Â ½Å°ø¿©ÀÚÀÇ ±âÁõ ÈÄ ¾ÈÀü¼º¿¡ ´ëÇÑ ¿¬±¸ ³ªÁØä(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(234È£) 14:10~14:15 Epidemiology study of bladder and urethral injury; A Korean nationwide population-based study À±¿µÀº(ÇѾç´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(235È£) 14:15~14:20 »óºÎ¿ä°ü ¼Õ»óÀÇ ¿ªÇבּ¸ : A Korean nationwide population-based study Źü½Ä(°í·Á´ëÇб³ ¾È»êº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(236È£) 14:20~14:25 ´ëÇѺñ´¢ÀÇÇаú ºÐ¾ß¿¡¼ ½ÃÇàÇÑ ¸ÞŸºÐ¼® ¹× ü°èÀû °íÂû ¿¬±¸¿¡ ´ëÇÑ ÁúºÐ¼® À̽¿í(ÇѾç´ëÇб³ ±¸¸®º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(237È£) 14:25~14:30 ºñ´¢ÀÇÇаú ¿Ü·¡¸¦ ¹æ¹®ÇÏ´Â 40¼¼ ¹Ì¸¸ ¼ºÀÎÀÇ Áúȯ ºÐÆ÷ ¹Ú°æ¹Î(°æºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(238È£) 14:30~14:35 ºÎºÐ ½Å ÀýÁ¦¼ú¿¡¼ ÀΰøÁö´ÉÀ» ÀÌ¿ëÇÑ 3D ÇÁ¸°Æà ½Ã¹°·ÊÀÌ¼Ç ¸ðµ¨ÀÇ Àû¿ë °æÀ±¼ö(¿ï»ê´ëÇб³ ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(239È£) 14:35~14:40 Epidemiology study of testicular injury; A Korean nationwide population-based study ¿À°æÁø(Àü³²´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(240È£) 14:40~14:45 ±¸ºÎ¿äµµÇùÂø ȯÀÚ¿¡¼ ½ÃÇàµÈ ÀýÁ¦ ¹× ÀÏÂ÷¿¬°á¼úÀÇ ¼ö¼ú ¼ºÀû ¼±Àοµ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(241È£) 14:45~14:50 ½ÅÀå°ø¿©ÀÚ¿¡¼ÀÇ delta-neutrophil index Æò°¡¸¦ ÅëÇØ ½ÅÀå ±â´É ȸº¹ ±âÀü¿¡ ´ëÇÑ ÀÌÇØ ¹ÚÁö¼ö(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(242È£) 14:50~15:00 Epidemiology and treatment patterns of the testicular torsion using a national database ÃÖÁøºÀ(°¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(243È£) 15:00~15:05 Partial nephrectomy using Zero Vs Warm ischemia :Effect on renal function preservation over a long term follow up Althubiany(severence hospital Yonsei university)
±³À°½Ã°£ 10-31 ¼¿ï COEX(244È£) 15:05~15:10 Would MP-MRI exclude patients from Active surveillance when they are eligible? mohammed(severence hospital yonsei university)
±³À°½Ã°£ 10-31 ¼¿ï COEX(245È£) 15:10~15:15 DA-9401 prevents adriamycin-induced testicular toxicity in Sprague-Dawley rats Karna(Institute for Medical Sciences Chonbuk National University Medical School – Biomedical Research and Institute and Clinical Trial Center for Medical Devices Chonbuk National University Hospital)
±³À°½Ã°£ 10-31 ¼¿ï COEX(246È£) 15:15~15:20 RAPN Outcomes in patient with PADUA ¡Ã 10 : Single Surgeon & Single Center Experience Almujalhem(Yonsei University)
±³À°½Ã°£ 10-31 ¼¿ï COEX(247È£) 15:20~15:25 Do we understand the supranormal DRF well? Agzamkhodjaev(Tashkent Pediatric Medical Institute)
±³À°½Ã°£ 10-31 ¼¿ï COEX(248È£) 15:25~15:30 Age related Re-operation after TIP procedure in Children with Hypospadias Abdullaev(¾ç»êºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(249È£) 15:30~15:35 RT-PCRÀ» ÀÌ¿ëÇÑ ¾Èµå·Î°Õ ¼ö¿ëü °ËÃâÀ» À§ÇÑ ¼Òº¯ÀÇ Á¦Á¶ ¹× ºÐ¼® ÈÄ´Ù ³ªÁî¹°(ºÎ»ê´ëÇк´¿ø ÀÇ»ý¸í°úÇÐ ¿¬±¸¼Ò)
±³À°½Ã°£ 10-31 ¼¿ï COEX(250È£) 15:35~15:40 Multiple primary cancers in men with sporadic or familial prostate cancer: its clinical implications ±èÁøÇõ(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(251È£) 15:40~15:45 Impact of Modified Bladder Neck Suspension on Early Recovery of Continence after Robot-Assisted Radical Prostatectomy(RARP) ½Åµ¿È£(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(252È£) 15:45~15:50 Strategy for prostate cancer patients with low prostate specific antigen level (2.5 to 4.0 ng/mL) Á¤ÀçÈÆ(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(253È£) 15:50~15:55 Outcomes of pathologically localized high-grade prostate cancer after radical prostatectomy in adjuvant treatment-naïve patients: a re-evaluation 2019 ÇãÁöÀº(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(254È£) 15:55~16:00 Usefulness of bi-parametric magnetic resonance imaging with b = 1800 s/mm©÷ diffusion-weighted imaging for diagnosing clinically significant prostate cancer ¼Û¿øÈÆ(¾ç»êºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(255È£) 16:00~16:05 °æÇÇÀû ½ÅÀý¼®¼úÀÇ ÇÕº´Áõ¿¡ ´ëÇÑ ¿¹ÃøÀÎÀÚ ¹Ú½Ã±Õ(ºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(256È£) 16:05~16:10 ³»½Ã°æ-°áÇÕ ½ÅÀå³» °á¼®¼ö¼úÀÇ ¼º°ø·üÀÌ ¹ÌÄ¡´Â ÀÎÀÚ ºÐ¼® Á¤Çصµ(¿ø±¤´ëÇб³ ºÎ¼Óº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(257È£) 16:10~16:15 ³²¼º ÇϺΠ¿ä°ü °á¼® ȯÀÚ¿¡¼ ºÎºÐ ¸¶ÃëÇÏ °æ¼º ¿ä°ü°æ °á¼® ¼ö¼úÀÇ È¿¿ë¼º ¹× ¾ÈÁ¤¼º¿¡ ´ëÇÑ ¿¬±¸ À̽ſì(°æ»ó´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(258È£) 16:15~16:20 ¿ä·Î°á¼® ȯÀÚ¿¡¼ °á¼® ¹Ðµµ¸¦ ¿¹ÃøÇϱâ À§ÇÑ ¼Òº¯°Ë»çÀÇ ÀÓ»óÀû À¯¿ë¼º Á¤¿øÈ£(°è¸í´ëÇб³ µ¿»êº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(259È£) 16:20~16:25 ½ÄÀÌ¿ä¹ýÀ» º´ÇàÇÏÁö ¾ÊÀº ¿ä·Î°á¼® ȯÀÚ¿¡¼ °á¼®¼ººÐ¿¡ µû¸¥ Àç¹ß·ü ºñ±³ À̽ÂÀ±(Ä¥°î°æºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(260È£) 16:25~16:30 Twenty-four hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis ÀÌÈñÀ±(ÃæºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(261È£) 16:30~16:35 ºñÁ¶¿µÀü»ê´ÜÃþÃÔ¿µ ¿µ»ó Hounsfield unit parameter ¸¦ ÀÌ¿ëÇÑ ¿ä°ü°á¼®ÀÇ Ã¼¿ÜÃæ°ÝÆļ⼮¼ú 1Â÷ ¼º°ø·ü ¿¹Ãø ¸ðµ¨ ±èÁØ(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(262È£) 16:35~16:40 Outcome of anterograde ureterography for radiolucent ureteral stone detection in extracoporeal shock wave lithotripsy. À¯ÀçÇü(ÀüºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(263È£) 16:40~16:45 ¹«Áõ»ó ½ÅÀå°á¼® ¹× Ãøº¹ÅëÀ» µ¿¹ÝÇÑ ½ÅÀå°á¼®ÀÇ Æ¯Â¡ ºñ±³ ¹Úµ¿Áø(°æºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(264È£) 16:45~16:50 ºñ¼ö¼úÀû ¿ä°ü°á¼® Ä¡·á¿¡ ÀÖ¾î¼ Ã¼°èÈµÈ À¯»ê¼Ò¿îµ¿ ÇÁ·Î±×·¥ÀÇ È¿°ú ÀÌ°æä(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(265È£) 16:50~17:00 °æ±¸Ç×ÀÀ°íÁ¦¸¦ º¹¿ëÇÏ´Â ½ÅÀå °á¼® ȯÀÚ¿¡¼ Ȧ·ý·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ ¿¬¼º³»½Ã°æ ¼ö¼úÀÇ ¾ÈÁ¤¼º ÀÌ°æä(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(266È£) 17:00~17:05 Initial Experiences of Laparoscopic Detrusorrhaphy Combined with Endoscopic injection ±è»ó¿î(¿¬¼¼ÀÇ´ë ½ÅÃ̼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(267È£) 17:05~17:10 ¿©¼º ¹æ±¤¾Ï ȯÀÚÀÇ ¿©¼º»ý½ÄÀå±â º¸Á¸ ÃÑü³» ·Îº¿ ±ÙÄ¡Àû¹æ±¤ ÀýÁ¦¼ú ¹× ½Å¹æ±¤Á¶Çü¼ú ³ëÅÂÀÏ(°í·Á´ëÇб³ ¾È¾Ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(268È£) 17:10~17:15 Èĺ¹¸·ÇÏ ¿äÃß ±³°¨½Å°æÀýÁ¦¼úÀ» ÀÌ¿ëÇÑ ¼öÁ·´ÙÇÑÁõÀÇ Ä¡·á Çã°æÀç(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(269È£) 17:15~17:20 ¹Ýº¹ÀûÀÎ ¿ä·Î°¨¿°À» À¯¹ßÇÏ´Â ¹æ±¤°Ô½ÇÀ» °¡Áø 3¼¼ ³²¾Æ¿¡¼ ±â¹æ±¤ ¹æ±¤°Ô½ÇÁ¦°Å¼ú ¹é¹Î±â(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(270È£) 17:20~17:25 Zynner syndrome case report ÀÌÀåÈñ(¿ï»ê´ëÇб³ ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(271È£) 17:25~17:30 ¾ç±Ø¼º ¿¡³ÊÁö¸¦ ÀÌ¿ëÇÑ ³»½Ã°æÀû Àü¸³¼± ÀûÃâ¼úÀÇ ÀÓ»óÀûÀÎ Àû¿ë°ú ´Ü°èº° ¼ú±â À±Áöȯ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(272È£) 17:30~17:35 ¿ä½Ç±ÝÀ» ÇÇÇϱâ À§ÇÑ °ý¾à±Ùº¸Á¸ HoLEP ¼ú±â ¿À½ÂÁØ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 10-31 ¼¿ï COEX(273È£) 17:35~18:00 ÀÓ»ó¿¡¼ÀÇ °æÇÇÀû ½ÅÀý¼®¼ú ¹× ¿¬¼º³»½Ã°æ ¼ö¼úÀÇ º´ÇÕ (ECIRS)¿¡ ´ëÇÑ ¹æ¹ý·ÐÀû °íÂû ¾ç½ÂÈÆ(¼¿ï´ëÇб³º´¿ø)